ARTICLE | Company News
In exchange for $30 million, ImmunoGen Inc. (NASDAQ:IMGN) and Sanofi (Euronext:SAN; NYSE:SNY) eliminated potential milestone and royalties payments the biotech was eligible to receive under two deals involving five compounds. The candidates are isatuximab, SAR408701, SAR566658, SAR428926 and an undisclosed antibody-drug conjugate (ADC).
Under the original deals, ImmunoGen and the pharma were co-developing ADCs developed using ImmunoGen's TAP and maytansinoid-based antibody-conjugate technologies...